TMX family genes and their association with prognosis, immune infiltration, and chemotherapy in human pan-cancer

Aging (Albany NY). 2023 Dec 21;15(24):15064-15083. doi: 10.18632/aging.205332. Epub 2023 Dec 21.

Abstract

Background: The thioredoxin (TMX) system, an important redox system, plays crucial roles in several immune-related diseases. However, there is limited research on the correlation of TMX family gene expression with human pan-cancer prognosis, tumor microenvironment (TME), and immunotherapy.

Methods: Based on the integration of several bioinformatics analysis methods, we explored the expression levels and prognostic value of TMX family members in pan-cancer and analyzed their association between TME, immune infiltration, stemness scores, and drug sensitivity. Using KEGG enrichment analysis, we explored the potential signaling pathways of their regulation. Additionally, we conducted a transwell assay to verify the relationship between TMX family gene expression and epithelial-mesenchymal transition (EMT) in liver cancer.

Results: Expression of the TMX family genes was shown to have an obvious intratumoral heterogeneity. In some cancers, TMX family members expression was also been found to correlate with poor prognosis of patients. Furthermore, TMX family genes may serve important roles in TME. The expression of TMX family genes was found to have a strong correlation with the stromal scores, immune scores, DNAss and RNAss in pan-cancer. Specifically, the expression levels of TMX family genes have been found to be associated with immune subtypes of renal clear cell carcinoma and liver hepatocellular carcinoma. High TMX2 expression promote EMT in liver cancer.

Conclusions: The findings of this study may elucidate the biological roles of TMX family genes as potential targets for pan-cancer and also offer valuable insights for further investigating how these genes function in the development and spreading of cancer.

Keywords: epithelial-mesenchymal transition; immune infiltration subtypes; pan-cancer; thioredoxin; tumor microenvironment.

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / genetics
  • Carcinoma, Renal Cell*
  • Humans
  • Kidney Neoplasms*
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / genetics
  • Prognosis
  • Thioredoxins* / genetics
  • Tumor Microenvironment / genetics

Substances

  • Thioredoxins
  • TMX2 protein, human